

# Induction of Endothelial Cell from Fibroblast by 5 Defined Factors



**Hyo-Soo Kim, MD, PhD, FAHA**

Director, National Research Laboratory for Cardiovascular Stem Cell,  
Seoul National University Hospital (SNUH),  
Seoul, Republic of Korea

# *Presenter Disclosure*


- Nothing to disclose


# Background

- New vessel formation using endothelial cells holds great therapeutic promise.
- ESC- or iPSC-derived ECs
  - Ethical hurdles
  - No standardized protocol
  - Necessity for complex manipulation of EB
  - Low differentiation efficiency
  - Risk of contamination by feeder cells


# Waddington's Epigenetic Landscape

Conventional concept





**No ethical hurdles**  
**No necessity for complex manipulation of EB**  
**No risk of contamination by feeder cells...**



# Aim:

- To develop a novel methodology providing **endothelial cells from fibroblasts** via **direct conversion**.



mesodermal progenitor cell

**Tal1, Gata2, Fli1**



hemangioblast




hematopoietic  
stem cell

**Ets family  
(ER71=Etv2,  
ETS-1, ELF-1, Erg)**

angioblast

**Ets family,  
Klf proteins**



endothelium


# Key T.F.s in EC development

- + Co-workers of endothelial transcription
  - **FOXO1, FOXC, LMO2** (co-factor)
- + Regulator of endothelial functions
  - **Klf2**




- **Target cells: adult fibroblast**
- **Species: mouse**
- **Read-out: tie2-GFP**

# 11 Candidate Factors


Gene symbol	Accession Number
Gata2	NM_008090
Foxc2	NM_013519
Elf1	NM_007920
Erg	NM_133659
Fli1	NM_008026
Tal1	NM_011527
Foxo1	NM_019739
Lmo2	BC057880
Ets1	BC010588
Er71(Etv2)	NM_007959
Klf2	NM_008452




Tie2-GFP Tg




# Series of ‘Single Factor’ Transduction Experiments






**Klf2  
on Foxo1/Er71**





**Tal1 out of 8**




**Lmo2 out of 7**








# 5 Key Factors for Endothelial Reprogramming






# EC markers during the Programming



# Lentiviral Silencing




# EC Markers after Endothelial Reprogramming




Before sorting by Tie2

# Induced Endothelial Cells: after Tie2 sorting

Mock-SFB




iEC




# iEC Characterization: RT-PCR

Relative mRNA expression


VE-cadherin




CD31









ICAM2







Tie2



# iEC Characterization: IF, EC Fx.




# iEC Characterization: Matrigel Tube Formation




# iEC Characterization: NO Production

After overnight incubation in 2 ng/ml VEGF, culture supernatants were harvested, and NO was assayed using a NO Detection Kit.




# Endothelial Epigenetics / Genetics


Bisulfite sequencing




Affymetrix GeneChip Mouse Gene 1.0 ST Array




## EC specific genes




11 factors



## Endothelium development (GO003158)




## Regulation of EC migration (GO0010594)




# Proliferation & Apoptosis of iECs



## Growth Curve





## Serum Starvation





# Universal Effect of iEC-5 Factors: TTF




# Effect of iEC-5 Factors on Monocytes



# Unique Effect of iEC-5 Factors: Compared with Rafii's 3 Factors




# Not Through Pluripotency Induction: Oct4-GFP SFBs




# Not Through Pluripotency Induction: Nanog-GFP SFBs


Unstained



Tie2-PE ab.  
stained



# Not Through Pluripotency Induction: Oct4/Nanog stay silent during trans-differentiation




# *In Vivo* Functionality of iECs


## Mouse Hindlimb Ischemia Model: D14



Gross Pictures

Mock-SFB  
iEC  
Primary EC  
MS1





LDPI






# Mouse Hindlimb Ischemia Model: Capillary Density




# In Vivo Engraftment Ratio = 10%




# In Vivo Participation as EC in Capillary: 0.3%


Mock-SFB




iEC



Primary EC



MS1



Ischemic limb harvest




D14


Whole cell lysis

BS1-lectin<sup>+</sup>  
endothelial cell


BS1-lectin<sup>+</sup> GFP<sup>+</sup>  
engrafted cell

# In Vivo Participation as EC : 0.3%






# iEC vs. ESC/iPSC-derived ECs



# Therapeutic Strategy



# Efficient Direct Reprogramming of Mature Amniotic Cells into Endothelial Cells by ETS Factors and TGF $\beta$ Suppression

Michael Gromberg,<sup>1</sup> Dayton James,<sup>1,2</sup> Bi-Sen Ding,<sup>1</sup> Daniel Nolan,<sup>1</sup> Fudan Gong,<sup>1</sup> Jason M. Butler,<sup>1</sup> William Schachterle,<sup>1</sup> Venkat Reddy,<sup>1</sup> Michael J. Hickey,<sup>1</sup> Christopher D. Dickey,<sup>1</sup> Lawrence A. Schwartz,<sup>1</sup> Olivier Elemento,<sup>5</sup> Sora Y. Rohr,<sup>1</sup> Howard Hagiwara,<sup>1</sup> and Juan Carlos Izpisua Belmonte,<sup>1,3</sup> Department of Cell Biology, Department of Bioengineering,<sup>2</sup> Department of Obstetrics and Gynecology,<sup>3</sup> Genomics Resources Core Facility,<sup>4</sup> Department of Pathology and Laboratory Medicine,<sup>5</sup> Icahn School of Medicine at Mount Sinai, New York, NY 10065, USA

<sup>1</sup>Howard Hagiwara, <sup>2</sup>Christopher D. Dickey, <sup>3</sup>Lawrence A. Schwartz, Department of Cell Biology, Department of Bioengineering,<sup>4</sup> Department of Obstetrics and Gynecology,<sup>5</sup>Genomics Resources Core Facility

<sup>1</sup>IRRH Prince Alwaleed Bin Talal Alzayez Alsaad Institute for Computational Biomedicine

Weill Cornell Medical College, New York, NY 10065, USA

<sup>2</sup>Ronald O. Perleman and Claudia Cohen Center for Reproductive Medicine, New York, New York 10065, USA

<sup>3</sup>Biobringing Program, Hofstra University, Hempstead, NY 11549, USA

<sup>4</sup>Correspondence: srodriguez@itsa.mssm.edu (S.Y.R.)

DOI: 10.1016/j.cell.2012.07.022

**SUMMARY** Endothelial progenitor pathways that modulate the hierarchical specification of pluripotent adult ECs. However, the cultivation of stable and proliferative clinical-scale has not been achieved. Adult-derived ECs have limited expansion potential. Likewise, differentiation of pluripotent stem cells, including induced pluripotent stem cells (iPSCs) and human embryonic stem cells (hESCs), into endothelial cells (ECs) results in the cells that proliferate poorly and drift into nonvascular lineages (James et al., 2010). Endothelial progenitor cells (EPCs) (Lyden et al., 2001; Rafi et al., 2002; Rafi and Lyden, 2003). In contrast, adult endothelial colony-forming cells (ECFCs) have significant expansion potential (Rafi et al., 2003; Rafi and Lyden, 2009). However, whether EPCs and ECFCs maintain their vascular identity after serial passages is unknown. The shortcomings of existing strategies for inducing vascular differentiation of hESCs and iPSCs to the armamentarium of regenerative medicine are evident in the study and treatment of ischemic pathologies.

**• Only amniotic cells**  
– Not readily available  
– Immunogenicity / allograft rejection

**• Not terminally differentiated FBs**

## INTRODUCTION

The generation of human endothelial cells (ECs) from nonvascular cell sources has great therapeutic potential for treatment of injured organs. Furthermore, this approach would help to

Cell 151, 1–17, October 26, 2012 © 2012 Elsevier Inc. 1

# Conversion of human fibroblasts to angioblast-like progenitor cells

Leo Kurian<sup>1,8</sup>, Ignacio Sancho-Martinez<sup>1,8</sup>, Emmanuel Nivat<sup>1,8</sup>, Aitor Aquirre<sup>1</sup>, Krystal Moon<sup>1</sup>, Caroline Pendares<sup>2</sup>, Ismael Volante<sup>1</sup>, Francisco J. Garcia-Cardena<sup>1</sup>, Sergio Roldan<sup>1</sup>, Constanza Cebrian<sup>1</sup>, Daniel Diaz-Ortega<sup>1</sup>, Francesca S Boscolo<sup>5,7</sup>, Rathi D Thiagarajan<sup>5,7</sup>, Fred H Gage<sup>4</sup>, Jeanne F Loring<sup>5,6</sup>, Louise C Laurent<sup>5,7</sup> & Juan Carlos Izpisua Belmonte<sup>1,3</sup>

**• Nat. Med., 2012**  
**• PNAS, 2012**  
**• Human amniotic cells → ECs**

**• 3 ETS factors:**  
ER71/ERG1/FLI1

**• Y' iPS4 factors:**  
OCT4/SOX2/KLF4/MYC

**• Via partial iPSC or cells capable of angiogenesis and reendothelialization in tissue-engineered vessels**

Andriana Margariti<sup>a</sup>, Bernard Winkler<sup>a</sup>, Eirini Karamitri<sup>a</sup>, Anna Zampetaki<sup>a</sup>, Tsung-neng Tsai<sup>a</sup>, Dilair Baban<sup>b</sup>, Jiannis Ragoussis<sup>b</sup>, Yi Huang<sup>c</sup>, Jing-Dong J. Han<sup>c</sup>, Lingfang Zeng<sup>a</sup>, Yanhua Hu<sup>a</sup>, and Qingbo Xu<sup>a,1</sup>

<sup>a</sup>Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; <sup>b</sup>Center for Human Genetics Research, Institute of Molecular Medicine, New York, NY 10032, USA; <sup>c</sup>Shanghai Center for Cell Engineering, Shanghai Jiaotong University, Shanghai 200032, China; <sup>1</sup>Department of Cell Biology, Max Planck Partner Institute for Computational Biology, Shanghai Institutes for Biological Sciences, Shanghai 200031, China

Edited by Shu Chien, University of California at San Diego, La Jolla, CA, and approved July 13, 2012 (received for review April 3, 2012)

The generation of induced pluripotent stem (iPSC) cells is an important tool for regenerative medicine. However, the main restriction is the risk of tumor development. In this study we found that during the early stages of somatic cell reprogramming toward a pluripotent state, specific gene expression patterns are altered. Therefore, we developed a method to generate partial-iPSC (PiPS) cells by transferring four reprogramming factors (OCT4, SOX2, KLF4, and c-MYC) to human fibroblasts for 4 d. PiPS cells did not form tumors *in vivo* and clearly displayed the potential to differentiate into endothelial cells (ECs) in response to defined media and culture conditions. To clarify the mechanism of PiPS cell differentiation into ECs, SET translocation (myeloid leukemia-associated) (SET) similar protein (SETSP) was identified to be induced during somatic cell reprogramming. Importantly, when PiPS cells were treated with VEGF, SETSP was translocated to the cell nucleus, directly bound to the VE-cadherin promoter, increasing vascular endothelial-cadherin (VE-cadherin) expression levels and EC differentiation. Functionally, PiPS-ECs improved neovascularization and blood flow recovery in a hindlimb ischemic model. Furthermore, PiPS-ECs displayed good attachment, stabilization, patency, and typical vascular structure when seeded on decellularized vessel scaffolds. These findings indicate that reprogramming of fibroblasts into ECs via

reprogramming may regulate signal pathways able to direct the differentiation of reprogrammed cells before the pluripotent state. Therefore, “skipping pluripotency” is a way to convert a somatic cell from one type to another. In this study we have established a method to generate partially induced pluripotent stem (PiPS) cells. This method includes transferring of the genes encoding the four transcription factors (OCT4, SOX2, KLF4, and c-MYC) to human fibroblasts, and culture in reprogramming media for 4 d. PiPS cells did not form tumors *in vivo* and had the potential to differentiate into ECs in response to defined media and culture conditions. We demonstrated that these PiPS cell-derived ECs are functional in angiogenesis in infarcted tissues in ischemic limb and in reendothelialization in tissue-engineered vessels *ex vivo*.

## Results

Alterations of Gene Expression During Fibroblast Cell Reprogramming as Early as Day 4. Human fibroblasts were virally transduced with genes encoding the four transcription factors OCT4, SOX2, KLF4, and c-MYC, cultured in reprogramming media for 4, 7, 14, and 21 d, and subjected to microarray analysis. The results revealed that 198 genes were altered at day 4, 107 genes at day 7, 97 genes at day

# Summary

- The first study demonstrating that adult fibroblasts can be directly converted to ECs by defined factors.
- These **iEC 5 factors** are Foxo1, Er71, Klf2, Tal1 and Lmo2.
- iECs exhibit endothelial features and functions *in vitro* and *in vivo*.

# Conclusions

- Our study provides further evidence that **cell fate determination is not eternal, but plastic** by the formation of new transcriptional network.
- Our findings identify the **molecular background of endothelial differentiation and trans-differentiation**.
- This study makes significant progress towards **future clinical application**.

# Direct Conversion of Adult Skin Fibroblasts to Endothelial Cells by Defined Factors

Jung-Kyu Han, MD\*; Sung-Hwan Chang, BS\*; Hyun-Ju Cho, PhD\*; Saet-Byeol Choi, BS\*;  
Hyo-Suk Ahn, MS; Jaewon Lee, BS; Heewon Jeong, BS; Seock-Won Youn, PhD;  
Ho-Jae Lee, BS; Yoo-Wook Kwon, PhD; Hyun-Jai Cho, MD; Byung-Hee Oh, MD;  
Peter Oettgen, MD; Young-Bae Park, MD; Hyo-Soo Kim, MD

**Background**—Cell-based therapies to augment endothelial cells (ECs) hold great therapeutic promise. Here, we report a novel approach to generate functional ECs directly from adult fibroblasts.

**Methods and Results**—Eleven candidate genes that are key regulators of endothelial development were selected. Green fluorescent protein (GFP)-negative skin fibroblasts were prepared from Tie2-GFP mice and infected with lentiviruses allowing simultaneous overexpression of all 11 factors. Tie2-GFP<sup>+</sup> cells (0.9%), representing Tie2 gene activation, were detected by flow cytometry. Serial stepwise screening revealed 5 key factors (Foxo1, Er71, Klf2, Tal1, and Lmo2) that were required for efficient reprogramming of skin fibroblasts into Tie2-GFP<sup>+</sup> cells (4%). This reprogramming strategy did not involve pluripotency induction because neither Oct4 nor Nanog was expressed after 5 key factor transduction. Tie2-GFP<sup>+</sup> cells were isolated using fluorescence-activated cell sorting and designated as induced ECs (iECs). iECs exhibited endothelium-like cobblestone morphology and expressed EC molecular markers. iECs possessed endothelial functions such as *Bandeiraea simplicifolia*-1 lectin binding, acetylated low-density lipoprotein uptake, capillary formation on Matrigel, and nitric oxide production. The epigenetic profile of iECs was similar to that of authentic ECs because the promoters of VE-cadherin and Tie2 genes were demethylated. mRNA profiling showed clustering of iECs with authentic ECs and highly enriched endothelial genes in iECs. In a murine model of hind-limb ischemia, iEC implantation increased capillary density and enhanced limb perfusion, demonstrating the *in vivo* viability and functionality of iECs.

**Conclusions**—We demonstrated the first direct conversion of adult fibroblasts to functional ECs. These results suggest a novel therapeutic modality for cell therapy in ischemic vascular disease. (*Circulation*. 2014;130:1168-1178.)

**Key Words:** cell transdifferentiation ■ endothelial cells ■ fibroblasts

## iEC Project

Jung-Kyu Han, MD

Sung-Hwan Chang,

Hyun-Ju Cho, PhD

Saet-Byeol Choi,

Hyo-Suk Ahn, MS

Jung-Soo Lee

## Fund

- Innovative Research Institute for Cell Therapy (IRICT), Korea
- National Research Foundation (NRF), Korea

